Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 18, 2018

View Archived Issues

Study identifies new target for combating HSV encephalitis

Gene Therapy Research Institution and Astellas sign option agreement on GT-0001X for ALS

Promising results presented for two next-generation TriKEs in solid tumors

Cannabics reports promising preclinical data on cannabinoid compound in cancer

JCR Pharmaceuticals announces plans to develop JR-441 for MPS IIIA

How to spot a good TB vaccine

Tau leads to clogged pores

Exome-derived circulating RNAs promote pancreatic cancer invasion and metastasis

Meta-analysis links aberrant brain activity to behavioral changes in psychopaths

CL-656 demonstrates promise in melanoma and colon cancer models

First-in-human data for CCR2-targeted PET tracer [64Cu]DOTA-ECL-1i

ALZ-801-derived 3-sulfopropanoic acid prevents Abeta42 oligomerization in Alzheimer's disease

Patient recruitment starts in two phase II trials of DMX-200 in kidney disease

FDA lifts partial clinical hold for XMT-1522

Biogen presents phase II data for BG-00011 in IPF patients

Toll-like receptor 4 antagonists discovered at TaiwanJ Pharmaceuticals

Phenex Pharmaceuticals identifies aryl hydrocarbon receptor antagonists

Galapagos, AbbVie Sarl present mutant CFTR modulators

CRISPR Therapeutics and ViaCyte partner on gene-edited allogeneic stem cell therapies for diabetes

GlaxoSmithKline patents hepatitis B e-antigen and/or surface antigen secretion inhibitors

Pfizer to evaluate Atomwise's platform for drug discovery

LEO Pharma and MorphoSys expand strategic alliance

Aurigene's oral CD47 antagonist AU7R-104 completing IND-enabling studies

European researchers present new data on compounds against Trypanosoma brucei

Sosei suspends HTL-0018318 clinical development following unexpected animal study finding

AmpliPhi Biosciences provides updates regarding the development of its bacteriophage therapeutics

Phase II trial of VK-2809 in patients with NAFLD and elevated LDL-C meets primary endpoint

IMV reports initial data from phase II trial of DPX-Survivac in DLBCL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...